bone marrow mesenchymal stromal cell therapy / Baylor College of Medicine - LARVOL DELTA

Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) (clinicaltrials.gov) - P1/2 | N=28 | Completed | Sponsor: Baylor College of Medicine | Recruiting ➔ Completed | N=66 ➔ 28 | Trial completion date: Oct 2023 ➔ Jan 2023 | Trial primary completion date: Oct 2023 ➔ Jan 2023

Enrollment change • Stroma • Trial completion • Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) (clinicaltrials.gov) - P1/2 | N=66 | Recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Oct 2022 ➔ Oct 2023 | Trial primary completion date: Oct 2022 ➔ Oct 2023

Stroma • Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) (clinicaltrials.gov) - P1/2; N=66; Recruiting; Sponsor: Baylor College of Medicine; N=30 ➔ 66

Clinical • Enrollment change • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases • PCR

Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) (clinicaltrials.gov) - P1/2; N=30; Recruiting; Sponsor: Baylor College of Medicine; Not yet recruiting ➔ Recruiting; Phase classification: P1 ➔ P1/2

Clinical • Enrollment open • Phase classification • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) (clinicaltrials.gov) - P1; N=30; Not yet recruiting; Sponsor: Baylor College of Medicine; Trial completion date: May 2022 ➔ Sep 2022; Initiation date: Aug 2020 ➔ Dec 2020; Trial primary completion date: May 2022 ➔ Sep 2022

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) (clinicaltrials.gov) - P1; N=30; Not yet recruiting; Sponsor: Baylor College of Medicine; Initiation date: May 2020 ➔ Aug 2020

Clinical • Trial initiation date • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) (clinicaltrials.gov) - P1; N=30; Not yet recruiting; Sponsor: Baylor College of Medicine

Clinical • New P1 trial